The prognostic impact of frailty in patients undergoing percutaneous mitral valve repair

Abstract

Aim: Percutaneous mitral valve repair (PMVR) with MitraClip® has proven to be an effective therapy to reduce mitral regurgitation in patients at high risk for conventional surgery. This population is currently characterized by advance age and high prevalence of comorbidities. Our aim was to evaluate the prevalence of frailty in a cohort of patients undergoing PMVR and its impact on clinical outcomes during follow-up.

Methods: A prospective registry was performed including all consecutive patients who underwent elective PMVR between June 2014 and March 2018 in our institution. Frailty was evaluated at admission with the functional FRAIL scale. In-hospital and 30-day procedural outcomes were collected. Clinical follow up was carried out including New York Heart Association (NYHA) functional class, heart failure hospitalization and death.

Results: Overall, 70 patients were included (mean age 75.3 ± 9.9 years, 65.7% male). Among them, 27 patients (38.6%) had a pre-procedural FRAIL score greater than 2, meeting frailty criteria. No differences between frail and non-frail patients were found in technical success (P = 1.0) or 30-day device success (P = 0.739). At six months follow up, both groups showed a significant improvement in NYHA functional class compared to baseline (frail: P = 0.002; non-frail: P < 0.001). During a median follow up of 675 (range 416-976) days, frailty patients had a higher incidence of HF admission and all-cause mortality (P = 0.013). In multivariate COX regression analysis, FRAIL score greater than 2 was significantly related to the primary composite endpoint (HR = 2.45; 95%CI: 1.02-5.88; P = 0.044).

Conclusion: Frailty was common in patients undergoing PMVR in our institution. Despite post-procedural clinical improvement, frailty was related to adverse outcomes in our series.

Keywords

Percutaneous mitral valve repair / mitral regurgitation / frailty

References

[1] Franzen O,Rudolph V,Knap M.Acute outcomes of MitraClip therapy for mitral regurgitation in high-surgical-risk patients: emphasis on adverse valve morphology and severe left ventricular dysfunction..Eur Heart J2010;31:1373-81

[2] Kortlandt FA,Bakker AL,Kelder JC.The predictive value of conventional surgical risk scores for periprocedural mortality in percutaneous mitral valve repair..Neth Heart J2016;24:475-80 PMCID:PMC4943886

[3] Díez-villanueva P,Vidán MT,Formiga F.Recomendaciones de la Sección de Cardiología Geriátrica de la Sociedad Española de Cardiología para la valoración de la fragilidad en el anciano con cardiopatía..Rev Esp Cardiol2019;72:63-71

[4] Zuern CS,Lubos E,Puls M.Influence of non-cardiac comorbidities on outcome after percutaneous mitral valve repair: results from the German transcatheter mitral valve interventions (TRAMI) registry..Clin Res Cardiol2015;104:1044-53

[5] Maisano F,Baldus S,Hausleiter J.Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe..J Am Coll Cardiol2013;62:1052-61

[6] Lancellotti P,Hagendorff A,Edvardsen T.Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging..Eur Heart J Cardiovasc Imaging2013;14:611-44

[7] Abellan van Kan G,Morley JE.Frailty: toward a clinical definition..J Am Med Dir Assoc2008;9:71-2

[8] Stone GW,Abraham WT,Généreux P.Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: Part 2: endpoint definitions: a consensus document from the mitral valve academic research consortium..J Am Coll Cardiol2015;66:308-21

[9] Wei CC,Tan G,Liu M.Impact of anemia on in-hospital complications after ischemic stroke..Eur J Neurol2018;25:768-74

[10] Afilalo J.Frailty in patients with cardiovascular disease: why, when, and how to measure..Curr Cardiovasc Risk Rep2011;5:467-72 PMCID:PMC3165117

[11] Sanchis J,Ruiz V,García-Blas S.Frailty and other geriatric conditions for risk stratification of older patients with acute coronary syndrome..Am Heart J2014;168:784-91

[12] Uchmanowicz I,Szeląg P,Łoboz-Grudzień K.Frailty in heart failure..Curr Heart Fail Rep2014;11:266-73

[13] Yanagawa B,Afilalo J,Arora RC.Frailty as a risk predictor in cardiac surgery: Beyond the eyeball test..J Thorac Cardiovasc Surg2019;157:1905-9

[14] Afilalo J,Kim DH,Piazza N.Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study..J Am Coll Cardiol2017;70:689-700

[15] Green P,Genereux P,Paradis JM.The impact of frailty status on survival after transcatheter aortic valve replacement in older adults with severe aortic stenosis: a single-center experience..JACC Cardiovasc Interv2012;5:974-81 PMCID:PMC3717525

[16] Metze C,Scherner M,Michels G.Impact of frailty on outcomes in patients undergoing percutaneous mitral valve repair..JACC Cardiovasc Interv2017;10:1920-9

[17] White HD,Alexander KP,Winters KJ.Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial..Eur Heart J Acute Cardiovasc Care2016;5:231-42

[18] Benito-gonzález T,Cardona JG,Ruiz MC.Akin I.Percutaneous treatment of mitral and tricuspid regurgitation in heart failure..Interventional Cardiology.2017;InTech

[19] Iliadis C,Kuhr K,Matzik AS.Functional status and quality of life after transcatheter mitral valve repair: a prospective cohort study and systematic review..Clin Res Cardiol2017;106:1005-17

[20] Stone GW,Abraham WT,Lim DS.Transcatheter mitral-valve repair in patients with heart failure..N Engl J Med2018;379:2307-18

[21] Obadia JF,Leurent G,Bonnet G.Percutaneous repair or medical treatment for secondary mitral regurgitation..N Engl J Med2018;379:2297-306

[22] Benito-González T,Villablanca PA,Iglesias-Gárriz I.Percutaneous mitral valve repair vs. stand-alone medical therapy in patients with functional mitral regurgitation and heart failure..Cardiovasc Revasc Med2020;21:52-60

[23] Moretti C,Murray S,Parviz Y.Prospective assessment of a palliative care tool to predict one-year mortality in patients with acute coronary syndrome..Eur Heart J Acute Cardiovasc Care2017;6:272-9

[24] Ellis G,Tsiachristas A,Burke O.Comprehensive geriatric assessment for older adults admitted to hospital..Cochrane Database Syst Rev2017;9:CD006211 PMCID:PMC6484374

[25] Steinvil A,Kiramijyan S,Rogers T.Utility of an additive frailty tests index score for mortality risk assessment following transcatheter aortic valve replacement..Am Heart J2018;200:11-6